NANO.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 11:35):

Stats
Today's Volume	30 853.00
Average Volume	48 354.00
Market Cap	305.75M
EPS	€0 ( 2024-05-22 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-6.01
ATR14	€0.0190 (0.29%)

Volume Correlation

Long: 0.05 (neutral)

Short: -0.24 (neutral)

Signal:(53.717) Neutral

Nanobiotix SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nanobiotix SA Correlation - Currency/Commodity

0.16
( neutral )

-0.11
( neutral )

0.00
( neutral )

0.31
( neutral )

0.08
( neutral )

Nanobiotix SA Financials

Annual	2023
Revenue:	€30.06M
Gross Profit:	€36.21M (120.46 %)
EPS:	€-1.080

FY	2023
Revenue:	€30.06M
Gross Profit:	€36.21M (120.46 %)
EPS:	€-1.080

FY	2022
Revenue:	€4.78M
Gross Profit:	€3.28M (68.59 %)
EPS:	€-1.640

FY	2021
Revenue:	€10 000.00
Gross Profit:	€0.00 (0.00 %)
EPS:	€-0.448

Financial Reports:

No articles found.

Nanobiotix SA Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Nanobiotix SA

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.